Tricida Stock Price, Forecast & Analysis (NASDAQ:TCDA)

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings results on Thursday, November, 14th. The company reported ($0.89) EPS for the quarter, hitting the consensus estimate of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

4 brokers have issued twelve-month target prices for Tricida's stock. Their forecasts range from $42.00 to $58.00. On average, they expect Tricida's stock price to reach $49.60 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for Tricida.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

News headlines about TCDA stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tricida earned a news impact score of -3.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Tricida.

Tricida saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,590,000 shares, an increase of 5.9% from the September 30th total of 3,390,000 shares. Based on an average daily trading volume, of 199,400 shares, the short-interest ratio is currently 18.0 days. Approximately 10.4% of the shares of the stock are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include Dr.Reddy's Laboratories (RDY), Reata Pharmaceuticals (RETA), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Allakos (ALLK), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), The Medicines (MDCO), Ocular Therapeutix (OCUL), SAGE Therapeutics (SAGE), Affimed (AFMD), Amarin (AMRN) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (0.64%), California Public Employees Retirement System (0.09%), Rhumbline Advisers (0.06%), Nisa Investment Advisors LLC (0.01%), Tower Research Capital LLC TRC (0.00%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Tricida stock include Beek Jeroen B Van, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA and Rhumbline Advisers. Company insiders that have sold Tricida company stock in the last year include Claire Lockey, Dawn Parsell Otto, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

TCDA stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Nisa Investment Advisors LLC, Tower Research Capital LLC TRC and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $37.19.

Tricida has a market capitalization of $1.84 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]